Lori Steelman

2.1k total citations · 1 hit paper
22 papers, 349 citations indexed

About

Lori Steelman is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Lori Steelman has authored 22 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Lori Steelman's work include Glioma Diagnosis and Treatment (16 papers), Radiomics and Machine Learning in Medical Imaging (9 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Lori Steelman is often cited by papers focused on Glioma Diagnosis and Treatment (16 papers), Radiomics and Machine Learning in Medical Imaging (9 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Lori Steelman collaborates with scholars based in United States, France and Netherlands. Lori Steelman's co-authors include Timothy F. Cloughesy, Patrick Y. Wen, Ingo K. Mellinghoff, Min Lu, Shuchi S. Pandya, Islam Hassan, Elizabeth A. Maher, Jennifer Clarke, Kha Le and Benjamin M. Ellingson and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Lori Steelman

21 papers receiving 347 citations

Hit Papers

Vorasidenib and ivosidenib in IDH1-mutant low-grade gliom... 2023 2026 2024 2025 2023 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
    2023 111 citations Ingo K. Mellinghoff, Min Lu et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lori Steelman United States 10 278 115 91 66 65 22 349
Maxime Fontanilles France 11 226 0.8× 133 1.2× 196 2.2× 81 1.2× 95 1.5× 31 480
Hongseok Yun South Korea 9 142 0.5× 85 0.7× 71 0.8× 52 0.8× 49 0.8× 44 262
Jeffrey Raizer United States 8 220 0.8× 114 1.0× 75 0.8× 34 0.5× 128 2.0× 12 390
Theophilos Tzaridis Germany 13 235 0.8× 156 1.4× 97 1.1× 30 0.5× 46 0.7× 27 401
Sigmund Hsu United States 9 318 1.1× 160 1.4× 88 1.0× 20 0.3× 116 1.8× 26 498
WK Alfred Yung United States 7 204 0.7× 206 1.8× 81 0.9× 47 0.7× 125 1.9× 17 384
Roxanne Marshall United States 5 265 1.0× 199 1.7× 152 1.7× 31 0.5× 87 1.3× 6 433
L. E. Abrey United States 6 386 1.4× 144 1.3× 106 1.2× 41 0.6× 108 1.7× 6 466
K. Carson United States 5 118 0.4× 139 1.2× 67 0.7× 41 0.6× 71 1.1× 16 345
Aurélie Bruno France 2 184 0.7× 84 0.7× 57 0.6× 103 1.6× 35 0.5× 3 259

Countries citing papers authored by Lori Steelman

Since Specialization
Citations

This map shows the geographic impact of Lori Steelman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori Steelman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori Steelman more than expected).

Fields of papers citing papers by Lori Steelman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori Steelman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori Steelman. The network helps show where Lori Steelman may publish in the future.

Co-authorship network of co-authors of Lori Steelman

This figure shows the co-authorship network connecting the top 25 collaborators of Lori Steelman. A scholar is included among the top collaborators of Lori Steelman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori Steelman. Lori Steelman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bent, Martin J. van den, Ingo K. Mellinghoff, Mehdi Touat, et al.. (2024). 10311- ACT-19 A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS. Neuro-Oncology Advances. 6(Supplement_4). iv9–iv9. 2 indexed citations
2.
Mellinghoff, Ingo K., Patrick Y. Wen, Jennie Taylor, et al.. (2024). CTNI-47. A PHASE 1, RANDOMIZED, PERIOPERATIVE TRIAL OF VORASIDENIB AND IVOSIDENIB IN IDH1-MUTANT DIFFUSE GLIOMA: UPDATED RESULTS. Neuro-Oncology. 26(Supplement_8). viii107–viii107. 2 indexed citations
3.
Mellinghoff, Ingo K., Martin J. van den Bent, Deborah T. Blumenthal, et al.. (2023). KS02.6.A INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE III STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION. Neuro-Oncology. 25(Supplement_2). ii4–ii5.
4.
Mellinghoff, Ingo K., Min Lu, Patrick Y. Wen, et al.. (2023). Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nature Medicine. 29(3). 615–622. 111 indexed citations breakdown →
5.
Mellinghoff, Ingo K., Martin J. van den Bent, Deborah T. Blumenthal, et al.. (2023). INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.. Journal of Clinical Oncology. 41(17_suppl). LBA1–LBA1. 8 indexed citations
6.
Cho, Nicholas S., Akifumi Hagiwara, Catalina Raymond, et al.. (2022). Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas. Neuro-Oncology Advances. 4(1). vdac124–vdac124. 9 indexed citations
7.
Ellingson, Benjamin M., Grace Hyun J. Kim, Jihey Lee, et al.. (2021). Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. Neuro-Oncology. 24(5). 770–778. 31 indexed citations
8.
Lu, Min, Timothy F. Cloughesy, Patrick Y. Wen, et al.. (2021). Impact of mutant IDH (mIDH) inhibition on DNA hydroxymethylation, tumor cell function, and tumor immune microenvironment (TIME) in resected mIDH1 lower-grade glioma (LGG).. Journal of Clinical Oncology. 39(15_suppl). 2008–2008. 5 indexed citations
9.
Mellinghoff, Ingo K., Martin J. van den Bent, Jennifer Clarke, et al.. (2020). RTID-05. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF VORASIDENIB (AG-881) VS PLACEBO IN PATIENTS WITH RESIDUAL/RECURRENT GRADE II GLIOMA WITH AN ISOCITRATE DEHYDROGENASE 1/2 (IDH1/2) MUTATION. Neuro-Oncology. 22(Supplement_2). ii194–ii194. 2 indexed citations
10.
Mellinghoff, Ingo K., Martin J. van den Bent, Jennifer Clarke, et al.. (2020). INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.. Journal of Clinical Oncology. 38(15_suppl). TPS2574–TPS2574. 11 indexed citations
11.
Mellinghoff, Ingo K., Katherine B. Peters, Timothy F. Cloughesy, et al.. (2020). Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.. Journal of Clinical Oncology. 38(15_suppl). 2504–2504. 3 indexed citations
12.
Lu, Min, Ingo K. Mellinghoff, Aarón Díaz, et al.. (2020). Abstract 2046: Inhibiting IDH mutations in low-grade glioma alters cellular function and the immune environment. Cancer Research. 80(16_Supplement). 2046–2046. 3 indexed citations
13.
Gultekin, Sakir H., et al.. (2020). Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1 -mutant glioblastoma: a case report from a Phase I study. CNS Oncology. 9(3). CNS62–CNS62. 22 indexed citations
14.
Aguado-Fraile, Elia, Sung Choe, Camelia Gliser, et al.. (2019). Abstract 2275: Detection of IDH1 mutations in plasma cell-free circulating tumor DNA (ctDNA) from patients with cholangiocarcinoma. Cancer Research. 79(13_Supplement). 2275–2275. 2 indexed citations
15.
Mellinghoff, Ingo K., Timothy F. Cloughesy, Patrick Y. Wen, et al.. (2019). A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.. Journal of Clinical Oncology. 37(15_suppl). 2003–2003. 23 indexed citations
16.
Mellinghoff, Ingo K., Marta Peñas-Prado, Katherine B. Peters, et al.. (2018). ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION. Neuro-Oncology. 20(suppl_6). vi18–vi18. 9 indexed citations
17.
Mellinghoff, Ingo K., Marta Peñas-Prado, Katherine B. Peters, et al.. (2018). Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.. Journal of Clinical Oncology. 36(15_suppl). 2002–2002. 24 indexed citations
18.
Flinn, Ian W., Carole B. Miller, Kirit M. Ardeshna, et al.. (2016). Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma. Blood. 128(22). 1218–1218. 18 indexed citations
19.
Casulo, Carla, Eric D. Jacobsen, Koen Van Eygen, et al.. (2016). Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma.. Journal of Clinical Oncology. 34(15_suppl). e19052–e19052. 5 indexed citations
20.
Casulo, Carla, Juan‐Manuel Sancho, Koen Van Eygen, et al.. (2016). Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab. Blood. 128(22). 2979–2979. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maxime Fontanilles Breakdown of academic impact, for papers by Hongseok Yun Breakdown of academic impact, for papers by Jeffrey Raizer Breakdown of academic impact, for papers by Theophilos Tzaridis Breakdown of academic impact, for papers by Sigmund Hsu Breakdown of academic impact, for papers by WK Alfred Yung Breakdown of academic impact, for papers by Roxanne Marshall Breakdown of academic impact, for papers by L. E. Abrey Breakdown of academic impact, for papers by K. Carson Breakdown of academic impact, for papers by Aurélie Bruno
Rankless by CCL
2026